Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus Infections (ADV-VSTS)
Open-Label Pilot Study of Haploidentical Donor Adenovirus Specific T Lymphocytes (ADV-VSTS) for the Treatment of Refractory Adenovirus Infection and/or Disease in Hospitalized Patients
Sponsor: Nationwide Children's Hospital
Listed as NCT04722029, this PHASE1/PHASE2 trial focuses on Adenovirus Infection and remains actively recruiting participants. Sponsored by Nationwide Children's Hospital, it has been updated 8 times since 2021, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Jun 2025 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Jun 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2022 — Oct 2023 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 3 earlier versions
-
Feb 2022 — Sep 2022 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Feb 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Nationwide Children's Hospital
For direct contact, visit the study record on ClinicalTrials.gov .